Læknablaðið - 01.03.2017, Síða 20

128 LÆKNAblaðið 2017/103
R A N N S Ó K N
ENGLISH SUMMARY
Background/Aims: Hepatitis C is a major cause of chronic liver disease
and cirrhosis in Western countries. Its treatment aims at eradicating the
virus and patients are considered cured if the virus is undetectable by
PCR in blood 12-24 weeks after end of treatment (sustained virological
response, SVR). The aim of this study is to investigate the results of
treating hepatitis C in Iceland during the period 2002-2012.
Materials and methods: Retrospective study including all patients
with hepatitis C receiving treatment with peginterferone and ribavirin
at Landspitali University hospital during the period 2002-2012. Pati-
ents who had been treated previously were excluded. Information was
obtained from medical records and the hospital pharmacy.
Results: A total of 207 patients were included, 136 (66%) males and
71 (34%) females. Mean age was 38 years (range 17-66). Genotyping
revealed that 71 (34%) patients had genotype 1, 135 (65%) genotype 3
and one genotype 2. A total of 147 (71%) patients achieved SVR. The
rate of SVR was 77.8% for genotype 3 and 57.7% for genotype 1. 9
patients (4%) had cirrhosis and 3 of them had SVR. Of 161 patients who
finished treatment per protocol, 87.5% and 77.1% with genotypes 3 and
1 respectively had SVR.
Conclusions: The study demonstrates higher rates of SVR in clinical
practice in Iceland compared to controlled clinical trials. The improved
effectiveness may be explained by younger patient population, low rate
of cirrhosis and close follow-up of patients.
Treatment of hepatitis C with peginterferon and ribavirin in Iceland from 2002-2012
Benedikt Friðriksson1, Óttar Már Bergmann2, Sigurður Ólafsson2
1Department of Medicine, 2Division of Gastroenterology and Hepatology, Landspítali - The National University Hospital of Iceland, Reykjavík.
Key words: Hepatitis C, peg-interferon, sustained virological response.
Correspondence: Sigurður Ólafsson, sigurdol@landspitali.is
Heimildir
1. Lavanchy D. The global burden of hepatitis C. Liver Int
2009; 29 Suppl 1: 74-81.
2. Gonzalez HC, Duarte-Rojo A. Virologic Cure of Hepatitis
C: Impact on Hepatic Fibrosis and Patient Outcomes. Curr
Gastroenterol Rep 2016; 18: 32.
3. Ara AK, Paul JP. New Direct-Acting Antiviral Therapies
for Treatment of Chronic Hepatitis C Virus Infection.
Gastroenterol Hepatol (N Y) 2015; 11: 458-66.
4. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti
M, et al. Ledipasvir and sofosbuvir for untreated HCV
genotype 1 infection. N Engl J Med 2014; 370: 1889-98.
5. Lawitz E, Gane EJ. Sofosbuvir for previously untreated
chronic hepatitis C infection. N Engl J Med 2013; 369: 678-
9.
6. Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M,
Younossi ZM, Corregidor A, et al. Simeprevir plus sofos-
buvir, with or without ribavirin, to treat chronic infection
with hepatitis C virus genotype 1 in non-responders to
pegylated interferon and ribavirin and treatment-naive
patients: the COSMOS randomised study. Lancet 2014;
384: 1756-65.
7. Welsch C, Jesudian A, Zeuzem S, Jacobson I. New direct-
-acting antiviral agents for the treatment of hepatitis C
virus infection and perspectives. Gut 2012; 61 Suppl 1:
i36-46.
8. Shiffman ML. Hepatitis C virus therapy in the direct acting
antiviral era. Curr Opin Gastroenterol 2014; 30: 217-22.
9. Feld JJ. Treatment indication and response to standard of
care with peginterferon and ribavirin in acute and chronic
HCV infection. Best Pract Res Clin Gastroenterol 2012; 26:
429-44.
10. Manns MP, McHutchison JG, Gordon SC, Rustgi VK,
Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus
ribavirin compared with interferon alfa-2b plus ribavirin
for initial treatment of chronic hepatitis C: a randomised
trial. Lancet 2001; 358: 958-65.
11. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G,
Gonçales FL Jr, et al. Peginterferon alfa-2a plus ribavirin
for chronic hepatitis C virus infection. N Engl J Med 2002;
347: 975-82.
12. Hauser G, Awad T, Brok J, Thorlund K, Štimac D,
Mabrouk M, et al. Peginterferon plus ribavirin versus
interferon plus ribavirin for chronic hepatitis C. Cochrane
Database Syst Rev 2014; 2: CD005441.
13. Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Solá
R, et al. Peginterferon alfa-2a and ribavirin for 16 or 24
weeks in HCV genotype 2 or 3. N Engl J Med 2007; 357:
124-34.
14. Sibley A, Han KH, Abourached A, Lesmana LA, Makara
M, Jafri W, et al. The present and future disease burden
of hepatitis C virus infections with today's treatment
paradigm - volume 3. J Viral Hepat 2015; 22 Suppl 4: 21-41.
15. Löve A, Stanzeit B. Hepatitis C virus infection in Iceland: a
recently introduced blood-borne disease. Epidemiol Infect
1994; 113: 529-36.
16. Swain MG, Lai MY, Shiffman ML, Cooksley WG, Zeuzem
S, Dieterich DT, et al. A sustained virologic response is
durable in patients with chronic hepatitis C treated with
peginterferon alfa-2a and ribavirin. Gastroenterology
2010; 139: 1593-601.
17. Hedenstierna M, Weiland O, Brass A, Bankwitz D,
Behrendt P, Uhnoo I, et al. Long-term follow-up of
successful hepatitis C virus therapy: waning immune
responses and disappearance of liver disease are
consistent with cure. Aliment Pharmacol Ther 2015; 41:
532-43.
18. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat
F, al. Histological grading and staging of chronic hepatitis.
J Hepatol 1995; 22: 696-9.
19. Hansen N, Obel N, Christensen PB, Kjær M, Laursen
AL, Krarup HB, et al. Effectiveness of treatment with
pegylated interferon and ribavirin in an unselected
population of patients with chronic hepatitis C: a Danish
nationwide cohort study. BMC Infect Dis 2011; 11: 177.
20. Ghany MG, Strader DB, Thomas DL, Seeff LB, Diseases
AAftSoL. Diagnosis, management, and treatment of hepa-
titis C: an update. Hepatology 2009; 49: 1335-74.
21. Marcellin P, Cheinquer H, Curescu M, Dusheiko GM,
Ferenci P, Horban A, et al. High sustained virologic
response rates in rapid virologic response patients in the
large real-world PROPHESYS cohort confirm results from
randomized clinical trials. Hepatology 2012; 56: 2039-50.
22. Innes HA, Hutchinson SJ, Allen S, Bhattacharyya D,
Bramley P, Carman B, et al. Ranking predictors of a
sustained viral response for patients with chronic hepa-
titis C treated with pegylated interferon and ribavirin in
Scotland. Eur J Gastroenterol Hepatol 2012; 24: 646-55.
23. SÁÁ. Ársrit SÁÁ 2007-2010. SÁÁ: Samtök áhugafólks um
áfengis- og vímuefnavandann, Reykjavík 2010.
24. Abergel A, Hezode C, Leroy V, Barange K, Bronowicki
JP, Tran A, et al. Peginterferon alpha-2b plus ribavirin
for treatment of chronic hepatitis C with severe fibrosis:
a multicentre randomized controlled trial comparing two
doses of peginterferon alpha-2b. J Viral Hepat 2006; 13:
811-20.
25. Di Marco V, Almasio PL, Ferraro D, Calvaruso V, Alaimo
G, Peralta S, et al. Peg-interferon alone or combined with
ribavirin in HCV cirrhosis with portal hypertension: a
randomized controlled trial. J Hepatol 2007; 47: 484-91.
26. Poynard T, Bedossa P, Opolon P. Natural history of liver
fibrosis progression in patients with chronic hepatitis
C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC
groups. Lancet 1997; 349: 825-32.
27. Chung RT, Andersen J, Volberding P, Robbins GK, Liu
T, Sherman KE, et al. Peginterferon Alfa-2a plus ribavirin
versus interferon alfa-2a plus ribavirin for chronic hepa-
titis C in HIV-coinfected persons. N Engl J Med 2004; 351:
451-9.
28. Lagging M, Langeland N, Pedersen C, Färkkilä M, Buhl
MR, Mørch K, et al. Randomized comparison of 12 or 24
weeks of peginterferon alpha-2a and ribavirin in chronic
hepatitis C virus genotype 2/3 infection. Hepatology 2008;
47: 1837-45.
29. Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V,
Persico M, et al. Peginterferon alfa-2b and ribavirin for 12
vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005;
352: 2609-17.
30. Mecenate F, Pellicelli AM, Barbaro G, Romano M,
Barlattani A, Mazzoni E, et al. Short versus standard
treatment with pegylated interferon alfa-2A plus ribavirin
in patients with hepatitis C virus genotype 2 or 3: the cleo
trial. BMC Gastroenterol 2010; 10: 21.
31. von Wagner M, Huber M, Berg T, Hinrichsen H, Rasenack
J, Heintges T, et al. Peginterferon-alpha-2a (40KD) and
ribavirin for 16 or 24 weeks in patients with genotype 2 or
3 chronic hepatitis C. Gastroenterology 2005; 129: 522-7.